Roth MKM Maintains Buy on Panbela Therapeutics, Maintains $25 Price Target

Moomoo 24/7 ·  Mar 27 11:59

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment